(Q37873372)

English

Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials

scientific article published on 07 May 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

0 references

1 reference

Europe PubMed Central

Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

based on heuristic

inferred from title

author name string

Wen-Bin Zhou

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Qiang Ding

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Ling Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Xiao-An Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Shui Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

0 references

publication date

7 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

128

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

625-631

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Toxicity of antiestrogens

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Quantitative synthesis in systematic reviews

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1556-5

21 January 2018

Identifiers

10.1007/S10549-011-1556-5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37873372&oldid=2201040503"